No results for ‘’
Nectar Lifescience Ltd
₹11.44
(1.63%)
Sat, 20 Jun 2026, 03:10 pm
Health Technology
Pharmaceuticals: Major
24.5KNectar Lifescience Price to Cash Flow Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.47 | 6.50 | 5.59 | 4.45 | 8.44 | 5.20 | 7.35 | 4.10 | 8.74 | 12.51 | 15.70 | 14.25 | 11.35 | 8.06 | 6.98 | 0 | 21.53 | 0 | 135.20 | 0 |
| Price to book ratio | 1.99 | 0.97 | 1.08 | 0.57 | 1.31 | 0.74 | 0.69 | 0.40 | 0.59 | 0.86 | 0.89 | 0.78 | 0 | 0.35 | 0.20 | 0.39 | 0.50 | 0.33 | 0.63 | 0.54 |
| Price to sales ratio | 1.39 | 0.68 | 0.57 | 0.32 | 0.93 | 0.51 | 0.41 | 0.22 | 0.33 | 0.50 | 0.51 | 0.48 | 0.32 | 0.14 | 0.09 | 0.27 | 0.32 | 0.23 | 0.40 | 0.31 |
| Price to cash flow ratio | 0 | 45.65 | 2.78 | 2.25 | 0 | 0 | 7.20 | 1.34 | 4.22 | 21.39 | 16.66 | 8.96 | 0 | 3.95 | 1.37 | 0 | 29.83 | 6.36 | 4.50 | 5.35 |
| Enterprise value | 498Cr | 681Cr | 877Cr | 905Cr | 1351Cr | 1299Cr | 1556Cr | 1224Cr | 1391Cr | 1718Cr | 1777Cr | 1654Cr | 1538Cr | 1265Cr | 979Cr | 1295Cr | 1381Cr | 1092Cr | 1290Cr | 1078Cr |
| Enterprise value to EBITDA ratio | 8.18 | 8.42 | 6.92 | 6.40 | 6.88 | 5.80 | 6.79 | 4.22 | 4.83 | 6.46 | 7.40 | 7.32 | 6.46 | 4.74 | 4.41 | 11.62 | 8.67 | 19.84 | 8.35 | 0 |
| Debt to equity ratio | 0.84 | 1.91 | 1.71 | 2.32 | 0.97 | 1.10 | 1.33 | 1.01 | 0.93 | 0.97 | 1.01 | 0.87 | 0.90 | 0.82 | 0.69 | 0.85 | 0.79 | 0.71 | 0.59 | 0.61 |
| Return on equity % | 28.26 | 21.69 | 29.61 | 18.04 | 19.98 | 15.37 | 9.73 | 10.38 | 6.92 | 7.03 | 5.67 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | -2.25 | 0.47 | -11.23 |
Nectar Lifescience Ltd Price to Cash Flow Ratio
The Nectar Lifescience Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Nectar Lifescience Ltd's valuation, profitability, and overall financial performance. Tracking the Nectar Lifescience Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Nectar Lifescience Ltd (NSE: NECLIFE, BSE: 532649) is currently trading at ₹11.44, with a market capitalization of ₹223.4Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Nectar Lifescience Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Nectar Lifescience Ltd Price to Cash Flow Ratio Current Value
The current Nectar Lifescience Ltd Price to Cash Flow Ratio stands at 5.35.
The latest Nectar Lifescience Ltd Price to Cash Flow Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Nectar Lifescience Ltd Price to Cash Flow Ratio Historical Trend
The Nectar Lifescience Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 5.35
- 2023: 4.50
- 2022: 6.36
- 2021: 29.83
- 2020: 0
The recent rise in Nectar Lifescience Ltd Price to Cash Flow Ratio suggests strengthening valuation trends and improving market sentiment.
What Nectar Lifescience Ltd Price to Cash Flow Ratio Indicates for Investors
The Nectar Lifescience Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Nectar Lifescience Ltd Price to Cash Flow Ratio Analysis Summary
The Nectar Lifescience Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Nectar Lifescience Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Nectar Lifescience Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.